Last reviewed · How we verify
PEK Fusion Protein Vaccine
PEK Fusion Protein Vaccine is a Biologic drug developed by HealthBanks Biotech Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | PEK Fusion Protein Vaccine |
|---|---|
| Sponsor | HealthBanks Biotech Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL (PHASE2)
- Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEK Fusion Protein Vaccine CI brief — competitive landscape report
- PEK Fusion Protein Vaccine updates RSS · CI watch RSS
- HealthBanks Biotech Co., Ltd. portfolio CI
Frequently asked questions about PEK Fusion Protein Vaccine
What is PEK Fusion Protein Vaccine?
PEK Fusion Protein Vaccine is a Biologic drug developed by HealthBanks Biotech Co., Ltd..
Who makes PEK Fusion Protein Vaccine?
PEK Fusion Protein Vaccine is developed by HealthBanks Biotech Co., Ltd. (see full HealthBanks Biotech Co., Ltd. pipeline at /company/healthbanks-biotech-co-ltd).
What development phase is PEK Fusion Protein Vaccine in?
PEK Fusion Protein Vaccine is in Phase 1.